Psychemedics Corporation Announces Record First Quarter Revenues DECLARES 67th CONSECUTIVE QUARTERLY DIVIDEND

ACTON, Mass., May 7, 2013 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced first quarter financial results for the period ended March 31, 2013.  The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of May 17, 2013 to be paid on May 30, 2013.  This will be the Company's 67th consecutive quarterly dividend.

(Logo:  http://photos.prnewswire.com/prnh/20111107/NE00639LOGO)

The Company's revenue for the quarter ended March 31, 2013 was $6.4 million versus $6.2 million for the quarter ended March 31, 2012, an increase of 3%.  Net income for the quarter ended March 31, 2013 was $822 thousand or $0.16 per diluted share, versus $827 thousand or $0.16 per diluted share, for the comparable period last year.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said,

"We are very pleased to report record sales for any first quarter in the Company's history. This is also in comparison to our highest growth quarter last year.  Our investment in sales and marketing continues to pay off as our new business growth accounted for the entire gain in the quarter, as well as offsetting the decline in our base business due to the weak hiring/jobs environment. 

During the quarter, we also completed the majority of the transition to our new patented screening process.  While we are expecting many benefits from this new patented technology, including an increase in capacity, the ability to expedite new tests to market, and reduced operating costs, there was a negative impact on profits for the quarter.  However, this negative impact was offset by a one-time insurance reimbursement for legal expenditures (in other income) and a positive tax impact from a 2012 R&D tax credit.  Our pre-tax profit margin was still 20%.

"We continue to have a strong balance sheet with more than $2.5 million in cash and cash equivalents as of March 31, 2013 with no long term debt, despite heavy investment in new equipment and software.  

"Our directors share our confidence in the long-term future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we move forward. 

"Therefore, the Board has declared a $0.15 dividend for the quarter.  This is our 67th consecutive quarterly dividend."

Psychemedics Corporation is the world's largest provider of hair testing for the detection of drugs of abuse. The Company's patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods.

The Psychemedics web site is www.psychemedics.com

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, growth opportunities, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with the development of markets for new products and services offered, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.

Contact:                         

Neil Lerner


Vice President of Finance


(978) 206-8220


Neill@psychemedics.com

 

Psychemedics Corporation

Statements of Income and Comprehensive Income

(UNAUDITED)



Three Months Ended


March 31,


2013


2012









Revenues

$6,432,442


$6,243,855

Cost of revenues

2,945,171


2,578,735





Gross profit

3,487,271


3,665,120









Operating Expenses:




   General & administrative

993,711


995,441

   Marketing & selling

1,126,658


1,124,825

   Research & development

164,710


168,048





Total Operating Expenses

2,285,079


2,288,314





Operating income

1,202,192


1,376,806

Other income

91,413


510





Net income before provision for income taxes

1,293,605


1,377,316





Provision for income taxes

471,260


549,825





Net income and comprehensive income

$822,345


$827,491





Basic net income per share

$0.16


$0.16





Diluted net income per share

$0.16


$0.16





Dividends declared per share

$0.15


$0.15





Weighted average common shares outstanding, basic

5,272,647


5,235,422





Weighted average common shares outstanding, diluted

5,292,686


5,244,042





 

Psychemedics Corporation

Balance Sheets

(UNAUDITED)



March 31,


December 31,


2013


2012





ASSETS




 Current Assets:




   Cash and cash equivalents

$2,512,665


$3,065,785

   Accounts receivable, net of allowance for doubtful accounts




       of $123,445 in 2013 and $121,583 in 2012

4,871,764


4,620,768

   Prepaid expenses and other current assets

1,009,269


823,274

   Income tax receivable

345,578


854,212

   Deferred tax assets  

252,573


209,877





Total Current Assets

8,991,849


9,573,916





Fixed Assets, net of accumulated amortization and depreciation




       of $4,598,240 in 2013 and $4,395,605 in 2012

4,331,392


4,201,409





   Other assets

384,736


345,293





Total Assets

$ 13,707,977


$  14,120,618





LIABILITIES AND SHAREHOLDERS' EQUITY








Current Liabilities:




   Accounts payable

$754,597


$669,789

   Accrued expenses

773,605


1,413,541





Total Current Liabilities

1,528,202


2,083,330





   Deferred tax liabilities, long-term

814,619


814,619

Total Liabilities

2,342,821


2,897,949





Commitments and Contingencies (Note 7)




Shareholders' Equity:




   Preferred-stock, $0.005 par value, 872,521 shares authorized,




        no shares issued or outstanding

--


--

   Common stock, $0.005 par value; 50,000,000 shares authorized




       5,941,715 shares issued in 2013 and 5,940,558 shares issued 2012 

29,709


29,703

   Additional paid-in capital

28,571,765


28,460,764

   Accumulated deficit

(7,154,529)


(7,186,009)

   Less - Treasury stock, at cost, 668,130 shares in 2013 and 2012

(10,081,789)


(10,081,789)





Total Shareholders' Equity

11,365,156


11,222,669





Total Liabilities and Shareholders' Equity

$13,707,977


$14,120,618





 

SOURCE Psychemedics Corporation



RELATED LINKS
http://www.psychemedics.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.